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Background: Chemokine (C-X3-C motif) ligand 1 (CX3CL1)/ CX3C chemokine receptor 1 (CX3CR1) signaling is
important in modulating the communication between neurons and resident microglia/migrated macrophages in
the central nervous system (CNS). Although CX3CR1 deficiency is associated with an improved outcome following
ischemic brain injury, the mechanism of this observation is largely unknown. The aim of this study was to
investigate how CX3CR1 deficiency influences microglia/macrophage functions in the context of its protection
following brain ischemia.
Methods: Wild-type (WT) and CX3CR1-deficient (CX3CR1−/−) mice were subjected to transient middle cerebral artery
occlusion (MCAO) and reperfusion. The ischemic brain damage was monitored by rodent high-field magnetic resonance
imaging. Neurological deficit was assessed daily. Neuronal apoptotic death and reactive oxygen species (ROS) production
were analyzed by immunostaining and live imaging. Activation/inflammatory response of microglia/macrophage were
assessed using immunohistochemistry, flow cytometry, 5-bromo-2-deoxyuridine labeling, cytokine ELISA, and real-time PCR.
Results: CX3CR1−/− mice displayed significantly smaller infarcts and less severe neurological deficits compared to WT
controls, following MCAO. In addition, CX3CR1−/− MCAO mice displayed fewer apoptotic neurons and reduced ROS
levels. Impaired CX3CR1 signaling abrogated the recruitment of monocyte-derived macrophages from the periphery,
suppressed the proliferation of CNS microglia and infiltrated macrophage, facilitated the alternative activation (M2 state)
of microglia/macrophages, and attenuated their ability to synthesize and release inflammatory cytokines.
Conclusion: Our results suggest that inhibition of CX3CR1 signaling could function as a therapeutic modality in ischemic
brain injury, by reducing recruitment of peripheral macrophages and expansion/activation of CNS microglia and
macrophages, resulting in protection of neurological function.
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Ischemic brain injury elicits an inflammatory response
that involves activation of microglia and monocyte-
derived macrophages in the central nervous system
(CNS). Within the lesion, these cells adopt unique mo-
lecular phenotypes with either protective or detrimental* Correspondence: Fu-Dong.Shi@dignityhealth.org
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reproduction in any medium, provided the oreffects on neuron survival [1]. Despite this basic under-
standing, the mechanisms controlling functional diver-
sity in microglia/macrophages remain elusive but
undoubtedly include differential signaling via chemo-
kines, cytokines, and other cues present in the ischemic
microenvironment.
The chemokine (C-X3-C motif ) ligand 1 (CX3CL1)/
CX3C chemokine receptor 1 (CX3CR1) signaling path-
way has been shown to play an important role in the
maintenance of neural-immune communication in
health and disease [2,3]. Fractalkine (CX3CL1), a
membrane-bound chemokine, is expressed predomin-
antly by neurons in the healthy CNS [4,5] while itsd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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microglia and on peripheral immune cell populations
including macrophages [6,7]. CX3CR1 selectively modu-
lates microglia activity in response to its ligand CX3CL1
[6]. CX3CL1/CX3CR1 also regulates recruitment of cir-
culating leukocytes to sites of injury [8,9].
Under neuroinflammatory conditions, loss of sig-
naling via CX3CR1 has been shown to have either
protective [10,11], or detrimental effects [12], or no
effects at all [13,14]. These conflicting observations
indicate the complexity and disease-specific regula-
tion of neuron-microglia communication via CX3CL1
and CX3CR1. In regards to acute CNS injury models
(transient and permanent brain ischemia, spinal cord
injury), the collective data suggest that the absence
of CX3CR1 significantly reduces ischemic damage
and inflammation [15-17].
Although the processes of microglia activation, cyto-
kine production, and phagocytosis have been studied in
several animal models of ischemia injury in CX3CR1-
deficient (CX3CR1−/−) mice, it remains unclear as to
how CX3CR1 deficiency alters the function of these
cells, resulting in reduced damage during ischemic injury
(highlighted by several controversial findings). Following
induction of focal cerebral ischemia within CX3CR1−/−
mice, no difference was observed in the number of IL-
1β-expressing microglia; rather, decreased leukocyte
infiltration is involved in the development of smaller in-
farcts [15]. Conversely, in an animal model of spinal
cord injury, modest but significantly more recruited
monocytes (CD45hi) accumulate in the spinal cord of
CX3CR1−/− mice by 3 days post-injury [16]; however, a
decrease in the number of CD11b+/Ly6Clo/iNOS+ mac-
rophages after 7 days post-injury was associated with re-
duced neuropathology and enhanced functional recovery
in these CX3CR1-deficient mice [16]. To date, little is
known about the CX3CL1/CX3CR1 pathway in the con-
text of microglia activation following brain ischemia.
In the current study, using a murine model of transi-
ent middle cerebral artery occlusion (MCAO), we tested
the consequences of the absence of CX3CR1 on micro-
glia/macrophage proliferation/recruitment and on their
neurotoxicity after brain ischemia. We find that loss of
CX3CR1 signaling attenuates the monocyte recruitment,
the expansion of resident microglia and newly recruited
monocytes, and reduced their inflammatory capacity




Breeding pairs of CX3CR1−/− mice were obtained from
The Jackson Laboratory (Bar Harbor, ME, USA). Knock-
outs were generated by replacing the second exon of theCX3CR1 gene with the enhanced green fluorescent pro-
tein (GFP) reporter gene, and backcrossed for more than
10 generations to C57BL/6 [13]. Cells under control of
the endogenous CX3CR1 locus (that is, microglia, mac-
rophages, dendritic cells, and so forth) in homozygote
CX3CR1−/− mice are labeled with GFP and also lack
CX3CR1 receptor function. Wild-type (WT) C57BL/6
mice were purchased from Taconic (Oxnard, CA, USA).
All animals were housed in pathogen-free conditions at
the animal facilities of the Barrow Neurological Institute,
Phoenix, AZ, USA. All experimental procedures were
approved by the Institutional Animal Care and Use
Committee of the Barrow Neurological Institute and
performed according to the Revised Guide for the Care
and Use of Laboratory Animals.
Transient middle cerebral artery occlusion and
reperfusion
Adult male mice (aged 10 to 14 weeks, weight 24 to
27 g) were exposed to transient (90 minutes) focal cere-
bral ischemia induced by occlusion of the right middle
cerebral artery using an intraluminal filament method
[18,19]. The production of an infarct was confirmed by
2,3,5-triphenyltetrazolium chloride (TTC) [20]. The met-
hodology for MCAO and TTC staining is detailed in
Additional file 1: Supplementary Methods.
Neurological deficit assessment
Daily neurological deficit assessment was performed by
investigators blinded to the control and MCAO groups
as described previously [19]. Rating scale: 0 = no deficit,
1 = failure to extend left forepaw, 2 = decreased grip
strength of left forepaw, 3 = circling to left by pulling the
tail, and 4 = spontaneous circling.
Cerebral blood flow, apparent diffusion coefficient
values, and T2-weighted images by rodent magnetic
resonance imaging
Magnetic resonance imaging (MRI) was performed on a
7-T small animal MRI, 30-cm horizontal-bore magnet, and
BioSpec Avance III spectrometer (Bruker Daltonics Inc.,
Fremont, CA, USA). In order to assess whether the ische-
mia and reperfusion were induced successfully, single slice
cerebral blood flow (CBF) images were acquired before
MCAO, 1 hour after MCAO and 24 hours after reperfu-
sion, using a Continuous Arterial Spin Labeling sequence.
Multiple Segments Echo Planer Imaging sequences were
used to acquire apparent diffusion coefficient (ADC) values
30 minutes after MCAO to assess the damage volume. T2-
weighted images were acquired 24 and 72 hours after
MCAO to evaluate the development of ischemic lesions,
using a Rapid Acquisition with Refocused Echoes sequence.
Detailed methodologies for these imaging are available in
Additional file 1: Supplementary Methods. MRI data were
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Numerics Inc., Germantown, MA, USA) on a LINUX
workstation.
Reactive oxygen species assessment in vivo
Reactive oxygen species (ROS) generated in the brain
were assessed in live mice by using the Xenogen IVIS200
imager (Caliper Life Sciences, Alameda, CA, USA) [21].
Briefly, mice were intraperitoneally injected with 200 mg/kg
Luminol (Invitrogen, Carlsbad, CA, USA). After 10 mi-
nutes, bioluminescence images were captured with expos-
ure time of 3 minutes. A region of interest tool was used to
measure the chemiluminescent intensity of the whole brain.
Data were collected as photons per second per centimeter
squared using the Living Image software (Caliper Life
Sciences).
Immunohistochemistry
Terminally anesthetized mice were perfused intracardially
with saline followed by 4% paraformaldehyde. The fixed
brains were embedded in paraffin and cut into serial 6 μm
thick coronal slides. Immunohistochemistry was per-
formed with antibodies against Iba-1 (Wako Chemicals
USA Inc., Richmond, VA, USA) to identify macrophages
and microglia; 4-hydroxy-2-nonenal (4-HNE; Abcam,
Cambridge, MA, USA) and 8-hydroxy-2-deoxyguanosine
(8-OHdG; Abcam) to identify lipid peroxidation and dam-
aged DNA of oxidative impairment. Immunolabeling was
detected by applying the peroxidase-antiperoxidase pro-
cedure with 3,3′-diaminobenzidine as a co-substrate. For
double immunofluorescent staining, antibodies against
NeuN (Millipore, Billerica, MA, USA) and cleaved
Caspase-3 (Cell Signaling, Danvers, MA, USA) were used
to identify apoptotic neurons. Respective negative controls
that omit primary antibodies and positive controls were
applied for each case. The positive cells were counted at
20× magnification in matched sections. Results are pre-
sented as Iba-1+, 4-HNE+, 8-OHdG+ or cleaved-Caspase-
3+/NeuN+ cells per mm2 within areas measured from 20×
images using Image J.1.34vi software (National Institutes
of Health) [12].
Enzyme-linked immunosorbent assay
Brain homogenates were prepared from WT and
CX3CR1−/− mice 72 hours after MCAO. Animals were
anesthetized and the brains were removed and immediately
frozen in liquid nitrogen. The ipsilateral or contralateral
hemisphere was homogenized in RIPA buffer (10 μl/mg
brain, Sigma, St. Louis, MO, USA). Protein concentration
was measured with bicinchoninic acid Protein Assay kit
(Pierce, Appleton, WI, USA). The total protein concentra-
tion was adjusted to 1 mg/ml protein extract. The concen-
trations of IL-1β, IL-6, and TNF-α in brain homogenates
were quantified by enzyme-linked immunosorbent assay(ELISA) kits (BioLegend, San Diego, CA, USA) and con-
verted into pg/mg protein extract.
5-bromo-2-deoxyuridine labeling
In order to visualize proliferating mononuclear cells in
CNS, mice were injected intraperitoneally with 5-
bromo-2-deoxyuridine (BrdU) (50 μg/g of mouse weight
in saline, Sigma) immediately before the MCAO proced-
ure and again 24, 48, and 60 hours after surgery. At 72
hours after surgery, mice were anesthetized with isoflur-
ane and transcardially perfused with PBS. Brains were
removed, and microglia and invading leukocyte isolation
was performed according to the standardized protocol
described below.
Isolation of mononuclear cells from the central nervous system
The isolation of microglia and invading leukocytes are
based on discontinuous percoll gradients [22-24]. Briefly,
fresh brain tissues were removed from mice and cut
into ~2 mm pieces and incubated in 10 mM Hepes/NaOH
buffer (10 mM HEPES, 150 mM NaOH, 7 mM KCL, 1 mM
MgCl2, 1 mM MgCl2, 0.36 mM CaCl2) containing 1 mg/ml
collagenase (Sigma) for 1 hour at 37°C. The tissues were dis-
persed with a syringe, filtered through a 100-mm wire mesh,
and centrifuged at 2,000 rpm for 5 minutes at 4°C. After
centrifugation, cell pellets were resuspended in 15 ml 30%
Percoll (Amersham Biosciences, Piscataway, NJ, USA), and
centrifuged against 70% Percoll in a 50-ml tube for 15 mi-
nutes. The cell monolayer at the 30 to 70% Percoll interface
was collected and washed once for further staining.
Flow cytometry
Cell phenotype
The number of microglia/macrophage, their prolifera-
tion properties and inflammatory cytokine secretion
were analyzed by flow cytometry. Single cell suspensions
prepared from brain tissues were stained with fluores-
cently labeled antibodies: APC-CD45, PerCP-Cy5.5-CD45,
PE-Ly6G, BV421-Ly6G, PE-Cy7-CD11b, PerCP-Cy5.5-
BrdU, PE-IL-1β, V450-IL-6, or APC-TNF-α at designed
combination. All antibodies and the isotype controls were
purchased from BD Biosciences, San Jose, CA, USA. The
staining was performed according to the manufacturer’s
instructions and the details are available in Additional file 1:
Supplementary Methods. After staining, samples were ana-
lyzed using a FACSAria Ι flow cytometer (BD Biosciences).
To avoid the interference of GFP expressed on CX3CR1−/−
microglia/macrophage, fluors such as FITC and Alexafluor
488 that excite in the same spectrum at the same filter sets
as GFP were excluded and the proper compensation was
performed in flow cytometry. Subsequent data analyses
were completed using FACSDiva software or FCS Express 4
software (BD Biosciences).
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Microglia/macrophages were enriched from the single-cell
suspension of the ischemic hemisphere of MCAO mice
using CD11b MicroBeads (Miltenyi Biotec, Auburn, CA,
USA), and then sorted via APC-45/PE-Cy7-CD11b/BV421-
Ly6G makers from the remaining cells by FACSAria I using
Diva software (BD Biosciences). Purity of microglia and
macrophages obtained by this approach reached 99%.
Quantitative real-time polymerase chain reaction analysis
Total RNA was extracted from the sorted microglia/
macrophages using the RNeasy Micro Kit (Qiagen,
Germantown, MD, USA) according to the manufacturer’s
instructions; 1 μg was used to synthesize the first strand of
cDNA using the Superscript First-Strand Synthesis System
for real-time PCR (Invitrogen). PCR was performed on the
Opticon 2 Real-Time PCR Detection System (Bio-Rad,
Hercules, CA, USA) using corresponding primers (Table 1)
and iQTM SYBR Green Supermix (Bio-Rad). Cycle condi-
tions included heating for 5 minutes at 95°C, followed by
40 cycles of 30 seconds at 95°C, 30 seconds at 60°C, and
60 seconds at 72°C. A melt curve analysis was performed
to ensure specific amplification. For each target gene, rela-
tive levels of expression were normalized against house-
keeping gene GAPDH of the same sample. The relative
expression levels of the mRNAs were then reported as fold
changes versus sham controls.
Statistical analysis
Results are presented as the means ± SEM. Statistical dif-
ferences between two groups were evaluated by the two-
tailed unpaired Student’s t-test. Multiple comparisons
were performed with two-way analysis of varianceTable 1 Primer sets for murine genes
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TCCATGTC-3′accompanied by Bonferroni post-hoc test. Values of P <
0.05 were considered significant.Results
Reduction of infarct volume and neurological deficit by
CX3CR1 deficiency after middle cerebral artery occlusion
To ensure the success of the MCAO model, CBF of
right middle cerebral artery territory was examined at 24
hours before MCAO, and 1 hour and 24 hours following
MCAO using high-field MRI. Animals wherein ischemia
and reperfusion were induced successfully were selected
for further analysis (Additional file 1: Figure S1A). No
significant difference in CBF at baseline (WT, 171.3 ± 9.5
vs CX3CR1−/−, 174.2 ± 10.1 ml/100 g/min, P > 0.05), is-
chemia (WT, 33.5 ± 14.3 vs CX3CR1−/−, 31.2 ± 13.1 ml/
100 g/min, P > 0.05) and reperfusion (WT, 160.1 ± 15.1
vs CX3CR1−/−, 155 ± 12.3 ml/100 g/min, P > 0.05) was
observed between WT and CX3CR1−/− mice. Further-
more, ADC (measuring the magnitude of diffusion of
water molecules within cerebral tissue) was acquired 30
minutes after MCAO to assess the damage volume of ip-
silateral hemisphere (Additional file 1: Figure S1B, low
value on the left). No significant differences in damage
volume were observed between CX3CR1−/− and WT mice
(WT, 122.2 ± 8.3 mm3; CX3CR1−/−, 119.1 ± 6.7 mm3)
(Additional file 1: Figure S1C).
To assess the infarct volume, T2-weighted images were
acquired at 24 and 72 hours following MCAO. The in-
farct volume in WT mice was 36.5 ± 5.7 mm3 at 24
hours and increased to 45.8 ± 6.8 mm3 at 72 hours.
Within CX3CR1−/− mice, infarct volume was 26.9 ±
5.7 mm3 at 24 hours, and a modest but significant de-
crease (to 19.0 ± 4.9 mm3) was observed at 72 hours
(Figure 1A). Although there was no significant difference in
infarct volume at 24 hours between the two groups,
CX3CR1−/− mice showed markedly smaller infarct volume
at 72 hours relative to WT mice (P < 0.01, Figure 1B). The
infarct observed in MRI scan was confirmed by TTC stain-
ing (Additional file 1: Figure S1D).
To further assess the differential response to MCAO
in CX3CR1−/− and WT mice, the neurological deficit
was assessed daily following MCAO. WT mice had an
average clinical score of 2.4 ± 0.4 at 24 hours and 2.0 ±
0.3 at 72 hours, while CX3CR1−/− mice had clinical
scores of 2.0 ± 0.3 at 24 hours and 1.2 ± 0.2 at 72 hours
indicative of the beginning of recovery at 72 hours in
CX3CR1−/− mice but not in WT mice (Figure 1C).CX3CR1 deficiency attenuates neuronal apoptosis after
middle cerebral artery occlusion
Double staining with NeuN (neuron marker) and cleaved
Caspase-3 (apoptotic marker) was performed to investi-
gate whether CX3CR1-dependent differences observed
Figure 1 CX3CR1 deficiency attenuates infarct volume and neurological deficit after middle cerebral artery occlusion. (A) Infarct volume
was assessed by T2-weighted images at 24 and 72 hours post-ischemia. (B) Quantification of T2 images shows that the infarct volume was
attenuated by CX3CR1 deficiency 72 hours after middle cerebral artery occlusion (MCAO). P < 0.0001 for genotype, P = 0.0194 for time point, and
P = 0.0011 for interaction by two-way analysis of variance. **P < 0.01 by Bonferroni post-hoc tests. (C) Clinical assessment demonstrated that
CX3CR1−/− mice have better neurological deficit scores than wild-type (WT) mice 72 hours after MCAO. P = 0.0049 for genotype, P = 0.0262 for
time point, and P = 0.0062 for interaction by two-way analysis of variance. *P < 0.05 by Bonferroni post-hoc tests. n = 6 per group.
Tang et al. Journal of Neuroinflammation 2014, 11:26 Page 5 of 13
http://www.jneuroinflammation.com/content/11/1/26in the size of ischemic damage at 72 hours following
MCAO were associated with differential neuronal apop-
tosis in peri-infarct areas. More cleaved Caspase-3 posi-
tive cells were observed in WT mice compared to
CX3CR1−/− mice and co-localized with NeuN in most
apoptotic cells (Figure 2A). The number of cleaved
Caspase-3 positive neurons was 179.3 ± 15.6/mm2 in
WT mice and 95.1 ± 16.9/mm2 in CX3CR1−/− mice 72
hours after MCAO (P < 0.01, Figure 2B). To reveal the
phenotype of the other apoptotic cells, double staining
of cleaved Caspase-3 with Iba-1 or GFAP markers, re-
spectively, were employed. These experiments revealed
cleaved Caspase-3 positive staining within some micro-
glia and astrocytes (data not shown).Figure 2 CX3CR1 deficiency attenuates neuronal apoptosis after midd
Caspase 3 (red) and NeuN (green) antibodies in peri-infarct area of wild-typ
occlusion. (B) Quantification of Cleaved-Caspase 3/NeuN positive cells. CX3
peri-infarct zone. **P < 0.01 by Student’s t-test. n = 4 per group. Scale bars =Fewer microglia and macrophages in ipsilateral
hemisphere of CX3CR1−/− mice after middle cerebral
artery occlusion
Microglia activation plays an important role in the patho-
logical progression after stroke, and is regulated by
CX3CR1 [6,12]. To investigate the effects of CX3CR1 defi-
ciency upon these processes, expression of microglia/
macrophage activation marker Iba-1 was examined at dif-
ferent sites of the brain in WT and CX3CR1−/− mice 72
hours following MCAO (Figure 3A). In the ipsilateral hemi-
sphere of WT mice, the numbers of Iba-1 positive cells
in hippocampus, striatum, cortex and peri-infract area
(666.1 ± 50.0, 1132.8 ± 96.1, 730.9 ± 68.1, 489.4 ± 56.1/mm2)
were significantly higher than those in CX3CR1−/− micele cerebral artery occlusion. (A) Double staining with cleaved
e (WT) and CX3CR1−/− mice 72 hours after middle cerebral artery
CR1−/− mice have fewer Cleaved-Caspase 3+NeuN+ cells in the
50 μm.
Figure 3 (See legend on next page.)
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Figure 3 CX3CR1 deficiency attenuates infiltration and leads to a different M1/M2 polarization pattern on microglia /macrophages in
ipsilateral hemisphere of middle cerebral artery occlusion mice. (A) Staining with anti-Iba-1 antibody in the ipsilateral hippocampus,
striatum, cortex and peri-infarct zone of CX3CR1−/− and wild-type (WT) mice 72 hours after middle cerebral artery occlusion (MCAO). (B) Quantification
of Iba-1 positive cells. CX3CR1−/− mice have fewer Iba-1 positive cells (macrophages/microglia) in the ipsilateral hippocampus, striatum, cortex and
peri-infarct zone, while no differences are observed in these sites of the contralateral hemisphere. P < 0.0001 by two-way analysis of variance for
genotype, localization and interaction. *P < 0.05, **P < 0.01 by Bonferroni post-hoc tests. n = 4 per group. Scale bars = 50 μm. (C) Flow cytometry
analysis of CD45hi/CD11b+ and CD45low/CD11b+ cells isolated from the ipsilateral and contralateral hemispheres of CX3CR1−/− and WT mice 72 hours
after MCAO by gating on Ly6G− events (Ly6G vs FSC). (D) Quantification of the number of events in the CD45hi/CD11b+/Ly6G− (left) and CD45low/
CD11b+ /Ly6G– (right) gate. Statistical analysis shows CX3CR1−/− mice have fewer CD45hi/CD11b+/Ly6G− as well as CD45low/CD11b+ /Ly6G– cells in the
ipsilateral hemisphere. CD45hi/CD11b+/Ly6G−: P= 0.0001 for genotype, P< 0.0001 for localization and interaction by two-way analysis of variance. CD45low/
CD11b+/Ly6G−: P= 0.0112 for genotype, P< 0.0001 for localization, and P= 0.0152 for interaction by two-way analysis of variance. **P< 0.01 by Bonferroni
post-hoc tests. n= 4 per group. (E) Microglia/macrophage in ischemic hemisphere of CX3CR1−/− brain polarize toward the M2 phenotype. Real-time
reverse-transcription polymerase chain reaction was performed using total RNA extracted from sorted CD45+/CD11b+/Ly6G− microglia/macrophage at 72
hours after MCAO. Data are expressed as fold change vs sham-operated controls. **P< 0.01 with Student’s t-test for Ym1, Mcr1, and iNOS, respectively.
n= 4 per group.
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(Figure 3B). In the contralateral hemisphere, the numbers
of Iba-1 positive cells in the hippocampus, striatum and
cortex were similar (307.9 ± 15.5 vs 316.0 ± 14.6, 110.2 ±
11.5 vs 111.8 ± 9.7, 94.0 ± 8.6 vs 92.4 ± 13.1, WT vs
CX3CR1−/−) regardless of genotype (Figure 3B).
To further distinguish microglia from macrophages
within the Iba-1 positive cell population, flow cytometry
was used to delineate CD45low/CD11b+/Ly6G− (microglia)
and CD45hi/CD11b+/Ly6G− (macrophage/activated micro-
glia) sub-populations within ischemic lesions of WT and
CX3CR1−/− mice. As shown in Figure 3C,D, more macro-
phages/activated microglia infiltrated in the ischemia le-
sions in WT mice compared to CX3CR1−/− mice (34.1 ±
2.5% vs 15.9 ± 1.8%). In addition, WT mice displayed more
CD45low microglia than CX3CR1−/− mice (22.1 ± 2.3% vs
11.7 ± 2.1%, Figure 3C,D). Both cell populations were simi-
lar in WT and CX3CR1−/− mice in the control (non-ische-
mic) contralateral hemisphere (Figure 3C,D).
Following ischemia, activated microglia/macrophage
can potentially exert either a protective or detrimental
effect, suggesting that these cells may acquire different
phenotypes belonging to the classical (M1) or to the al-
ternative (M2) active status. We found that activated
M1-like Iba-1+ cells, which have shorter and thicker pro-
cesses and bigger cell bodies, were visualized in the WT
brain section, while ramified M2-like Iba-1+ cells
were predominantly located in the CX3CR1−/− brain
(Figure 3A). To evaluate their M1/M2 polari-
zation, we sorted and purified microglia/macrophages
(CD45+/CD11b+/Ly6G−) from the ischemic hemisphere of
CX3CR1−/− and WT MCAO mice brain. Using real-time
PCR, we found that the levels of tested M1- and M2-type
genes in Fluorescence Activated Cell Sorter (FACS)-sorted
microglia/macrophages from WT mice were increased
starting from 1 day after MCAO and further elevated by 3
days post-MCAO (data not shown). Within CX3CR1−/−
microglia/macrophages, the M2-type genes (Ym1, Mcr1)
were significantly increased, whereas the M1-type gene(iNOS) was notably decreased compared to WT microglia/
macrophages when isolated at 72 hours after MCAO
(Figure 3E). These results suggest that deficiency of
CX3CR1 may facilitate the alternative activation (M2
state) of microglia/macrophages in stroke.
Reduced proliferation of macrophages and microglia in
ipsilateral hemisphere of CX3CR1−/− mice after middle
cerebral artery occlusion
To determine whether the decrease in CD11b+Ly6G–
cells observed in ischemic lesions of CX3CR1−/− MCAO
mice, in addition to decreased chemotaxis of monocytes,
was due to suppressed expansion of microglia/macro-
phage, we assessed proliferation of CD11b+Ly6G− cells.
Proliferation analysis was performed on populations of
CD45low/CD11b+/Ly6G− cells (microglia), and CD45hi/
CD11b+/Ly6G− cells (macrophage/activated microglia)
obtained from CX3CR1−/− and WT mice injected with
BrdU (Figure 4A). Quantitative analysis revealed a sig-
nificant 3-fold increase in the number of CD45low/
CD11b+/Ly6G−/BrdU+ cells in the ipsilateral relative to
the contralateral hemisphere in WT mice 72 hours after
stroke (Figure 4B). A significant reduction (71.1%) in the
number of proliferating CD45low/CD11b+/Ly6G− cells was
observed in the ipsilateral hemisphere in CX3CR1−/− com-
pared to WT mice (WT, 43.3 ± 4.1%; CX3CR1−/−, 12.5 ±
2.2%, P < 0.01, Figure 4B). There were no significant differ-
ences in the numbers of CD45low/CD11b+/Ly6G−/BrdU+
cells in the contralateral hemisphere between the two ex-
perimental groups, although CX3CR1−/− mice showed a
lesser trend (WT, 11.5 ± 2.9%; CX3CR1−/−, 6.7 ± 0.7%,
P > 0.05, Figure 4B). We also observed a modest but sig-
nificant reduction (23.2%) in the number of proliferating
CD45hi/CD11b+/Ly6G− cells in the ipsilateral hemisphere
in CX3CR1−/− compared with WT mice (WT, 42.1 ± 2.7%;
CX3CR1−/−, 32.3 ± 3.9%, P < 0.05). Collectively, these re-
sults indicate that CX3CR1 deficiency affects ischemic
injury-induced proliferation of resident microglia and
recruited macrophages.
Figure 4 Suppressed proliferation of CD45low/CD11b+/Ly6G− and CD45hi/CD11b+/Ly6G− cells in the ipsilateral hemisphere of
CX3CR1−/− mice after middle cerebral artery occlusion. (A) Flow cytometry analysis of proliferation of Ly6G– gated CD45low/CD11b+ (microglia)
and CD45hi/CD11b+ (macrophages/activated microglia) population with 5-bromo-2-deoxyuridine (BrdU) incorporation in the ipsilateral hemisphere of
wild-type (WT) and CX3CR1−/− mice 72 hours after middle cerebral artery occlusion (MCAO), compared to their contralateral (unlesioned) hemisphere
controls. CD45hi/CD11b+/Ly6G− cell proliferation was not shown in the contralateral due to their very low to undetectable presence. (B) Graph presents
quantification of microglia/macrophage proliferation measured by flow cytometry. Data indicate a marked reduction in CD45low/CD11b+/Ly6G−
cell proliferation and a modest but significant reduction in CD45hi/CD11b+/Ly6G− cell proliferation in the ipsilateral hemisphere of CX3CR1−/− mice
compared to WT mice 72 hours after MCAO. P < 0.0001 for genotype and localization, P = 0.0017 for interaction by two-way analysis of variance.
*P < 0.05, **P < 0.01 by Bonferroni post-hoc tests. n = 4 per group.
Tang et al. Journal of Neuroinflammation 2014, 11:26 Page 8 of 13
http://www.jneuroinflammation.com/content/11/1/26CX3CR1 deficiency attenuates reactive oxygen species
generation in brain after middle cerebral artery occlusion
ROS, generated as by-products of cellular metabolism, have
long been known to be a component of the inflammatory
response after ischemia. To investigate whether CX3CR1
deficiency had effects upon ROS production, we assessed
ROS levels in live mice using the Xenogen IVIS200 imager
at 24 and 72 hours after MCAO. The chemiluminescence
detection of ROS was performed in the brains, specifically
in the ipsilateral hemisphere (Figure 5A). The mean chemi-
luminescence intensity of brain in WT mice was 1,090.3 ±127.4 p/s/cm2/sr (photons per second per centimeter
squared per steradian) at 24 hours and 850.9 ± 81.7 p/s/
cm2/sr at 72 hours. Within CX3CR1−/− mice, mean chemi-
luminescence intensity values were 1,350.9 ± 118.9 p/s/
cm2/sr at 24 hours and 641.7 ± 47.6 p/s/cm2/sr at 72 hours.
At 24 hours post-ischemia, no differences in ROS levels
were observed between the two groups (P > 0.05). At 72
hours post-ischemia, the ROS levels decreased significantly
in CX3CR1−/− mice compared to 24 hours (P < 0.01), while
no change was observed in WT mice (P > 0.05) (Figure 5B).
In addition, the oxidative impairment of neurons was
Figure 5 CX3CR1 deficiency attenuates reactive oxygen species generation in brain after middle cerebral artery occlusion. (A) Reactive
oxygen species (ROS) were evaluated by Xenogen IVIS200 imager in wild-type (WT) and CX3CR1−/− mice in vivo. (B) Quantification of ROS. No
difference in ROS levels were observed between the two groups 24 hours after MCAO. ROS level decreased in CX3CR1−/− mice 72 hours after
MCAO compared to 24 hours (P < 0.0001 for genotype and time point, P = 0.0036 for interaction by two-way analysis of variance; **P < 0.01
by Bonferroni post-hoc tests) and is significantly less in CX3CR1−/− mice relative to WT mice (*P < 0.05 by Bonferroni post-hoc tests). n = 6 per
group. p/s/cm2/sr, photons per second per centimeter squared per steradian. (C) Immunohistochemistry for 4-hydroxy-2-nonenal (4-HNE) and
8-hydroxy-2-deoxyguanosine (8-OHdG) in the ischemic lesion 24 and 72 hours after MCAO. (D) Reduction of the number of stained cells in the
CX3CR1−/− mice compared with WT mice. P < 0.0001 for genotype, P = 0.0003 for oxidative marker, and P = 0.9827 for interaction by two-way
analysis of variance. **P < 0.01 by Bonferroni post-hoc tests. n = 5 per group scale bars: 50 μm.
Tang et al. Journal of Neuroinflammation 2014, 11:26 Page 9 of 13
http://www.jneuroinflammation.com/content/11/1/26immunohistochemically assessed by stain for lipid peroxi-
dation with 4-HNE and damaged DNA with 8-OHdG
(Figure 5C). The number of stained cells in the CX3CR1−/−
mice was notably less compared with WT mice (P < 0.01)
(Figure 5D).
CX3CR1 deficiency impairs inflammatory signaling in
microglia and macrophage in ischemic brain
To determine whether CX3CR1 deficiency is associated
with changes in the expression of inflammatory media-
tors produced by activated macrophages and microglia,
ELISA was used to screen injured brain homogenates
for differences in cytokine production. Consistent with
previous reports [25-27], expression of a subset of in-
flammatory cytokines (IL-1β, IL-6, and TNF-α) was in-
creased after MCAO regardless of genotype. In WT
mice, the amounts of IL-1β, IL-6, and TNF-α were
160.9 ± 8.4, 56.5 ± 6.1, 253.0 ± 22.9 pg/mg in the ipsi-
lateral hemisphere and 80.7 ± 4.1, 19.2 ± 2.2, 101.9 ±
15.3 pg/mg in the contralateral hemisphere, respectively.In CX3CR1−/− mice, the amounts of IL-1β, IL-6, and
TNF-α were 94.2 ± 11.9, 29.0 ± 5.1, 191.9 ± 19.8 pg/mg in
the ipsilateral hemisphere and 74.5 ± 5.1, 15.5 ± 1.1,
116.5 ± 13.7 pg/mg in the contralateral hemisphere, re-
spectively. Notably, post-injury expressions of these cy-
tokines were markedly reduced in CX3CR1−/− mice in
the ipsilateral hemisphere, while no difference was ob-
served in the contralateral hemisphere (Figure 6A).
To determine whether deficient CX3CR1 signaling in
CNS microglia/macrophages could account for these
cytokine expression changes, a series of controlled
ex vivo flow cytometry assays were performed. Microglia
and macrophages were isolated from ischemic brains of
WT and CX3CR1−/− mice, followed by quantification of
IL-1β+/CD11b+/Ly6G–, IL-6+/CD11b+/Ly6G–, and TNF-
α+/CD11b+/Ly6G– cells using flow cytometry. Using this
approach, an increased expression of IL-1β, IL-6, and
TNF-α in CD11b+Ly6G– cells (fluorescent intensity in
Figure 6B) as well as the numbers of cytokine-expressing
CD11b+Ly6G– cells (event quantification in Figure 6C)
Figure 6 CX3CR1 deficiency impairs inflammatory signaling in microglia and macrophage in ischemic brain. (A) The amounts of IL-1β, IL-6,
and TNF-α in brain homogenates from wild-type (WT) and CX3CR1−/− mice 72 hours after middle cerebral artery occlusion (MCAO) were measured with ELISA.
IL-1β: P=0.0018 for genotype, P=0.0002 for localization, and P=0.0052 for interaction by two-way analysis of variance; IL-6: P= 0.0010 for genotype, P<0.0001
for localization, and P=0.0058 for interaction by two-way analysis of variance; TNF-α: P<0.0001 for genotype, P= 0.0240 for localization, and P= 0.0063 for
interaction by two-way analysis of variance. *P<0.05, **P<0.01 by Bonferroni post-hoc tests. n=4 per group. (B) IL-1β, IL-6, and TNF-α expression were analyzed
by flow cytometry within the CD11b+Ly6G– gate. Representative histograms show IL-1β, IL-6, and TNF-α expression in the contralateral (blue) and ipsilateral
(red) hemispheres of CX3CR1−/− and WT mice at 72 hours after MCAO. Mean fluorescent intensity is indicated within each representative histogram. (C) The
number of IL-1β, IL-6, and TNF-α-producing CD11b+Ly6G– cells was quantified from ischemic brain of CX3CR1−/− and WT mice at 72 hours after MCAO with
flowcytometry. IL-1β+/CD11b+/Ly6G–: P=0.0030 for genotype, P=0.0002 for localization, and P=0.0052 for interaction by two-way analysis of variance; IL-6+/
CD11b+/Ly6G–: P=0.0030 for genotype, P=0.0002 for localization, and P=0.0052 for interaction by two-way analysis of variance; TNF-α+/CD11b+/Ly6G–: P=0.0386
for genotype, P=0.0332 for localization, and P=0.0173 for interaction by two-way analysis of variance. *P<0.05 by Bonferroni post-hoc tests. n=4 per group.
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sions in WT mice (ipsilateral vs contralateral). This re-
sponse was noticeably absent from the injured brain of
CX3CR1−/− mice (Figure 6B,C). In the ipsilateral hemi-
sphere, CX3CR1−/− mice displayed significant reduction in
expression of IL-1β, IL-6, and TNF-α in CD11b+Ly6G– cells
and cytokine-expressing CD11b+Ly6G– cell numbers
(P < 0.05 vs WT, Figure 6B,C).
Discussion
The work presented here provides important in vivo evi-
dence for the role of the CX3CL1/CX3CR1 signaling
pathway in the activation and neurotoxicity of microglia/
macrophage in cerebral ischemia. Using CX3CR1−/−
mice, in which the CX3CR1 gene is substituted with the
gene for the GFP on both alleles (CX3CR1GFP/GFP), and
a murine model of transient brain ischemia, we find that
CX3CR1 deficiency resulted in a decrease in the size of
ischemic lesion, a decrease in the number of apoptotic
cells (predominantly neurons), marked deregulation of
post-ischemic brain inflammatory responses (including
ROS and pro-inflammatory cytokines), a significant de-
crease in proliferation of microglia and infiltrating mac-
rophages in the ischemic lesion, and a marked decrease
in the levels of IL-1β/IL-6/TNF-α expressed by micro-
glia/macrophage in ischemic brain. Collectively, these ef-
fects due to CX3CR1 deficiency correlate with improved
neurological function following MCAO and suggest that
blockade of CX3CR1/CX3CL1 signaling may provide
neuroprotection against ischemic injury.
Absence of fractalkine receptor in CX3CR1−/− mice has
been previously reported to be protective in ischemia. Crit-
ically, significantly smaller (56%) infarcts and blood–brain
barrier damage have been observed in CX3CR1−/− animals
compared with CX3CR1+/− and WT mice 72 hours after a
60-minute MCAO [15]. CX3CR1 deficiency has also been
shown to induce protection from a 30-minute MCAO
starting as early as 24 hours [17]. In an experimental model
of spinal cord injury, CX3CR1−/− mice demonstrate neuro-
protection and functional recovery 5 days post-injury [16].
In agreement with these previous studies on the role of the
CX3CL1/CX3CR1 pathway in acute CNS injury, our work
finds that mice lacking CX3CR1 are protected from ische-
mic injury 72 hours after a 90-minute MCAO. Interest-
ingly, we find prevention of exacerbation of ischemic lesion
was accompanied with reduced cleaved Caspase 3 positive
neurons in the peri-infarct area at 72 hours after initial
stroke in CX3CR1−/− mice compared to WT mice, incon-
sistent with a previous report [15]. While these observed
differences could be attributed to the differences in the ex-
perimental designs, the outcomes between our study and
others are identical. Further, it may also imply that the ef-
fects of CX3CL1/CX3CR1 signaling may be dependent
upon the context of the specific disease state.CX3CR1 deficiency has been suggested to attenuate
tissue damage and improve recovery of function by re-
ducing the recruitment and/or the activation of mi-
croglia and macrophages [15,28-30]. We tested this
hypothesis by isolating mononuclear cells from the in-
jured brain of WT and CX3CR1−/− mice, followed by
quantifying CD45+/CD11b+ cells by flow cytometry. We
find a significant decrease in CD45+/CD11b+/Ly6G–
microglia/macrophage in the ipsilateral hemisphere of
CX3CR1−/− mice vs WT mice, which was confirmed by
immunohistochemical staining with Iba-1 in brain sec-
tions. To determine whether this was a result of sup-
pressed microglia proliferation or decreased monocyte
recruitment, the relative expression of CD45 has been
used to differentiate resident microglia (CD45low) from
recruited monocytes (CD45hi) [31]. CD45low/CD11b+/
Ly6G– cells (microglia) predominate in the contralateral
side of both genotypes. However, by 72 hours post-
injury, accumulation of both CD45low (microglia)
and CD45hi (macrophage/activated microglia) CD11b+/
Ly6G– cells dramatically decreased in the ischemic
hemisphere of CX3CR1−/− mice. Moreover, BrdU assays
show that the proliferation of microglia (CD45low) is sig-
nificantly impaired in CX3CR1−/− MCAO mice. The
proliferation of CD45hi cells (including activated micro-
glia) was also suppressed; however, not to the extent
which could fully compensate for the decreased number
of CD45hi cells seen in CX3CR1−/− MCAO mice com-
pared to WT MCAO mice. We therefore speculate that
the migration of monocyte-derived macrophages from
the periphery was inhibited. These data together indi-
cate that both microglia/macrophage proliferation and
macrophage recruitment are attenuated by CX3CR1 de-
ficiency within the MCAO model. Our results coincide
with a previous study that demonstrated decreased leu-
kocytes infiltration as a possible mechanism for the de-
velopment of smaller infarcts in CX3CR1−/− mice after a
60-minute MCAO [15]. Conversely, more CD45hi cells
were found accumulated in the injured spinal cords of
CX3CR1−/− mice. Although the role of this cell popula-
tion is not clear (rather, this study revealed a distinct
monocyte subset), CD11b+/Ly6Clo/iNOS+ macrophages
were associated with reduced neuropathology and en-
hanced functional recovery [16]. Indeed, it has long been
thought that macrophage (microglia) are not a uniform
cell population, such that specific environmental signals,
including effector molecules, timing of activation, and
degree of injury, may induce their different polarization
states [32,33]. Therefore, phenotypically distinct mono-
cyte populations appear to be associated with tissue
pathology and repair in ischemia and, thus, warrant fur-
ther study [16].
Previous reports indicated a marked increase in proin-
flammatory cytokine levels that peak 12 to 24 hours after
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mice are in agreement with these temporal dynamics of
cytokines. As expected, an initial increase of TNF-α, IL-
1β, and IL-6 was detected in the ipsilateral hemisphere
after MCAO. However, contrary to the levels of proin-
flammatory cytokines observed in control samples, we
show that the ablation of proliferating microglia cells
and recruitment of monocytes, associated with CX3CR1
deficiency, resulted in a significant decrease in the levels
of IL-1β, TNF-α, and IL-6, suggesting an important tem-
poral deregulation of the proinflammatory cytokine re-
sponse. Similar patterns of mRNA expression and
temporal deregulations were observed in the NF-κB sig-
naling pathway, a general marker of inflammatory re-
sponse in cerebral ischemia [16]. Furthermore, using
flow cytometry, we confirmed that the trends of proin-
flammatory cytokines in the ipsilateral hemisphere of
the MCAO brain in CX3CR1−/− mice are consistent with
the levels secreted by CX3CR1−/− microglia/macrophage
isolated from MCAO brains. Therefore, it appears that
microglia/macrophage may play an important role in the
regulation/modulation of the proinflammatory responses
in cerebral ischemia, and their functions are attenuated
by CX3CR1 deficiency.
Variations of cell morphology or cell displacement are
related to the specific activity of microglia/macrophage
[32]. Following ischemia, activated microglia/macrophage
can potentially exert either a protective or detrimental ef-
fect, suggesting that these cells may acquire different phe-
notypes belonging to the classical (M1) or to the
alternative (M2) active status [35]. M1 activation is gener-
ally referred to as the pro-inflammatory and cytotoxic
phenotype, characterized by nitric oxide, ROS, and proin-
flammatory cytokine production, while the M2 phenotype
is an alternative activation state, associated with a fine tun-
ing of inflammation, scavenging of debris, promotion of
angiogenesis, tissue remodeling and repair [17,36]. Fuma-
galli and colleagues [17] reported that, in CX3CR1−/−
mice, protection from ischemia at early time points after
injury is associated with a protective inflammatory milieu,
characterized by the promotion of M2 polarization
markers. We found that activated M1-like Iba-1+ cells,
which have shorter and thicker processes and bigger cell
bodies, were visualized in the WT brain section, while
ramified M2-like Iba-1+ cells were predominantly located
in the CX3CR1−/− brain (Figure 3A) with increased ex-
pression of M2 markers (Figure 3E), implying that sup-
pressed activation of microglia/macrophage by CX3CR1
deficiency may be responsible for the neuroprotective ef-
fects in the CX3CR1−/− mice.
Conclusion
In summary, using a murine model of transient focal is-
chemia, we explored the consequences of CX3CR1absence on microglia/macrophage proliferation/recruit-
ment and on their activation after brain ischemia. When
CX3CR1 signaling is abolished, neurological recovery is
improved and neural pathology is reduced. Our data
show that loss of CX3CR1 signaling attenuates the pro-
liferation and inflammatory capacity of microglia/macro-
phages. Moreover, monocytes recruitment and/or the
differentiation of newly recruited monocyte subsets are
altered. Collectively, these data identify CX3CR1 as a pu-
tative therapeutic target for selectively reducing neuro-
destructive inflammatory cascades after stroke.
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